Spero Therapeutics, Inc. announced that effective as of July 2, 2022, Cristina Larkin will separate from the company as its Chief Operating Officer pursuant to the Restructuring. In connection with Ms. Larkin's separation, the Company and Ms. Larkin entered into a separation agreement (the “Larkin Separation Agreement”), dated as of May 3, 2022, and Ms. Larkin received notice pursuant to the Worker Adjustment and Retraining Notification Act of 1988 (the “WARN Act”). Effective as of the Effective Date, David Melnick, M.D. will separate from the Company as its Chief Medical Officer pursuant to the Restructuring.